Ondansetron Stada

Ondansetron, the active ingredient in Ondansetron Stada, is a 5-HT3 receptor antagonist presented as a strength/form for oral use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Ondansetron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron Stada is a selective 5‑HT3 receptor antagonist used to prevent and treat nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: helps control acute and delayed episodes in cancer patients. - Radiation‑induced nausea and vomiting: reduces the frequency and severity of symptoms during radiotherapy. - Post‑operative nausea and vomiting: decreases incidence of nausea after surgical procedures. - Pregnancy‑related nausea (hyperemesis gravidarum): provides relief when other treatments are ineffective. - Anticipatory nausea: lessens nausea that occurs before chemotherapy in patients with a history of severe CINV.

Ondansetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement difficulty. - Diarrhoea: loose stools in some patients. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with IV use. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Vision changes: blurred vision or visual disturbances.

When using Ondansetron Stada, consider the following precautions to ensure safe and effective therapy.

- Cardiac monitoring: assess baseline ECG in patients with known heart disease. - Drug interactions: review concomitant medications that may affect QT interval. - Renal impairment: adjust dosing in severe renal dysfunction. - Hepatic impairment: use caution in patients with liver disease. - Pregnancy and lactation: weigh benefits against potential risks. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Ondansetron may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Apomorphine: may cause profound hypotension and loss of consciousness. - Certain anti‑arrhythmic drugs (e.g., amiodarone, quinidine): increase risk of QT prolongation.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): potential for serotonin syndrome. - Antifungal azoles (ketoconazole, fluconazole): may increase plasma levels of ondansetron. - Macrolide antibiotics (erythromycin, clarithromycin): can affect cardiac conduction. - Chemotherapy agents (cisplatin, cyclophosphamide): additive QT‑prolonging effect. - Oral contraceptives: may reduce effectiveness of hormonal contraception.